| (Merck) MK-3475-966 | Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with advanced/Unresectable Biliary Tract Carcinoma | Kazemi, Dr Ghazaleh | Open to recruitment | NCT04003636 |
| (AstraZeneca) D933GC00001 / EMERALD-1 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma | Zbuk, Dr Kevin | Recruitment on hold - COVID-19 | NCT03778957 |
| (CCTG) CO.21 / CHALLENGE | A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients With High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE) | Goffin, Dr John | Recruitment on hold - COVID-19 | NCT00819208 |
| (EXELIXIS) XL184-312 / COSMIC-312 | A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Meyers, Dr Brandon | Recruitment on hold - COVID-19 | NCT03755791 |
| (H3 Biomedicine and Eisai) H3B-6527-G000-101 | An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma | Meyers, Dr Brandon | Recruitment on hold - COVID-19 | NCT02834780 |
| (UHN) OZM-067 / LuNET | A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment with individualized dosimetry in Patients with 68Ga-DOTATATE identified Somatostatin Receptor positive Neuroendocrine Tumors | Juergens, Dr Rosalyn | Recruitment on hold - COVID-19 | NCT02743741 |
| RTOG 1112 | Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma | Swaminath, Dr Anand | Recruitment on hold - COVID-19 | NCT01730937 |
Find a Trial
Contact Us